SCHEMBL21186209

SCHEMBL21186209

Nc1ccc(Oc2ccc(F)cc2Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 2/20 0.56
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
ALDH1A1 P00352 3/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SLC6A4 P31645 7/20 0.44
HTR2A P28223 6/20 0.44
KCNH2 Q12809 6/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A3 Q01959 2/20 0.44
PNLIP P16233 1/20 0.44
SCN9A Q15858 1/20 0.44
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31264488 1.00 PDE7A (0.56) PDE7AMAOAMAOBALDH1A1CYP3A4
SCHEMBL21186018 0.89 PDE7A (0.47) PDE7AALDH1A1SLC6A4HTR2AKCNH2
SCHEMBL2812244 0.86 MAOB (0.47) PDE7AMAOAMAOBALDH1A1CYP3A4
SCHEMBL4318630 0.85 PDE7A (0.63) PDE7AMAOAMAOBALDH1A1CYP3A4
SCHEMBL15955628 0.82 SLC6A4 (0.44) PDE7ASLC6A4HTR2AKCNH2SLC6A2
SCHEMBL4374841 0.81 HSPB1 (0.58) MAOAMAOBALDH1A1CYP3A4TSHR
SCHEMBL8904604 0.81 PDE7A (0.59) PDE7AMAOAMAOBALDH1A1CYP3A4
SCHEMBL554810 0.81 MAOA (0.61) PDE7AMAOAMAOBALDH1A1CYP3A4
SCHEMBL11018978 0.81 ALDH1A1 (0.50) PDE7AALDH1A1SLC6A4HTR2AKCNH2
SCHEMBL4367987 0.81 ST14 (0.50) MAOBSLC6A4HTR2AKCNH2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214976-A1 GPR35 MODULATORS AND USES THEREOF CROSSIGNAL THERAPEUTICS, INC. 2025-07-03 US disclosed
EP-4504712-A1 GPR35 MODULATORS AND USES THEREOF Crossignal Therapeutics, Inc. (US) 2025-02-12 EP disclosed
WO-2023196538-A1 GPR35 MODULATORS AND USES THEREOF CROSSIGNAL THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
WO-2019141980-A1 AGRICULTURAL CHEMICALS GLOBACHEM NV (BE) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214976-A1 GPR35 MODULATORS AND USES THEREOF GPR35, GPR34, GPR68 PDE7A 2644/4885MAOA 3766/4885MAOB 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.